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The purpose of this study was to review the literature regarding the action of the cytokines interleukin 10 (IL-10) and tumor
necrosis factor-alpha (TNF-α) in pregnancy and to emphasize the factors that are of interest to clinical obstetrics. The literature
highlights several actions of IL-10 and TNF-α during pregnancy. The actions of these cytokines seem to be antagonistic and
dependent on the balance between them, which is orchestrated by the speciﬁc immunosuppressive action of IL-10. TNF-α has
a characteristic inﬂammatory action, and it is an additional diabetogenic factor in pregnancy. The loss of the control of the
production of these cytokines, with increase of TNF-α, is related to the risk for developing obstetric complications, particularly
recurrent fetal loss, gestational diabetes mellitus, hypertensive syndromes, and fetal growth restriction. However, study results are
controversial and are not clearly deﬁned. These issues are attributed to the heterogeneity of the studies, particularly regarding
their sample sizes and sources, the evaluation methods, and the multiplicity of factors and conditions that inﬂuence cytokine
production. These questions are fundamental and should be addressed in future investigations to obtain more consistent results
t h a tc a nb ea p p l i e dt oo b s t e t r i cp r a c t i c e .
1.Introduction
Cytokines belong to a diverse family of small, soluble pro-
teins that are expressed by several cell types and tissues and
act as immunologic mediators. The subpopulations of these
cytokine-producing cells, which classically include T helper
1 (Th1) and T helper 2 (Th2) cells, play fundamental roles
in diﬀerentiating the nature of the immunologic response.
If Th1 cytokines predominate, the immune system will gen-
erate a cell-mediated response (cytotoxic type) that is tar-
geted at intracellular pathogens or cancer cells [1]. The Th2
subpopulation induces the production of antibodies against
pathogens and thus characterizes the humoral-type immu-
nologic response [2].
To date, at least 22 interleukin types have been identiﬁed
[3]. The Th1 and Th2 subpopulations were the ﬁrst classes to
be described, generally as with opposing action forms, and
they have been thoroughly studied [4]. In humans, the Th1
subpopulationisclassicallyrepresentedbyinterferongamma
(IFN-γ) and by interleukin 12 (IL-12). The Th2 subpopula-
tion is characterized by IL-4, IL-5, and IL-13 [5, 6]. Tumor
necrosis factor-alpha (TNF-α) and the interleukins 1-beta
(IL-1β) and IL-6 have clear proinﬂammatory actions and are
classiﬁed in the subpopulation of Th1 lymphocytes [6, 7].
Interleukin 10 (IL-10) is a special type of cytokine that,
in humans, plays a dual immunologic role that is either
stimulatory and counterregulatory or immunosuppressive.
This role excludes it from the Th1 and Th2 classes. However,
IL-10 was originally described as a Th2 cytokine because of
its anti-inﬂammatory action in rodents [6, 8, 9].
TNF-α is essential in the orchestration of the cytokine
cascade, and it is a therapeutic target in many inﬂammatory
diseases. The increased production of TNF-α has been
related to the pathogenesis of various diseases, including
rheumatoid arthritis, Crohn’s disease, atherosclerosis psori-
asis, sepsis, diabetes mellitus, and obesity [10].2 ISRN Obstetrics and Gynecology
In pregnancy, the immunologic system plays an impor-
tant role that ensures normal pregnancy development and to
promote the development of complications [11]. Pregnancy
success appears to rely on a discrete balance between the
cytokines Th1 and Th2, which are involved in fetal growth
and development [12]. TNF-α,I L - 1 β, and IL-6 are some of
the fundamental cytokines in early pregnancy. It participates
in blastocyst implantation and, adversely, in ﬁrst-trimester
losses. As pregnancy develops, high TNF-α concentrations
have been related to the development of preeclampsia and
gestational diabetes mellitus (GDM), reduced IL-10 levels,
and preterm birth [6, 7, 13, 14]. Placental mechanisms
are also involved in the regulation of the immunologic re-
sponse in pregnancy [15]. Trophoblastic and Hofbauer cells
in the placenta produce various cytokine types that ini-
tially have autocrine and paracrine functions, but they
may cause metabolic alterations following the formation of
placental villi if they reach maternal circulation [16]. Ac-
cording to the literature, the placenta may contribute to the
reduction of maternal immunologic responses and the loss
of its regulatory role can result in development of certain
complications, such as diabetes mellitus and preeclampsia
[14, 16, 17].
Because of the association between immunologic re-
sponses and obstetric outcomes, the early identiﬁcation of
immunologic alterations would facilitate the prevention of
adverse pregnancy outcomes. However, the immunologic
proﬁle of human pregnancy needs to be more clearly deﬁned
[6].
From the 1980s to the 1990s, maternal tolerance to allo-
antigens was explained by the predominance of Th2 immu-
nity over Th1 immunity, which protected the fetus from
maternal “attack”. Th1 predominance was observed in cases
of recurrent [18, 19] and spontaneous [18, 20] miscarriages
and preeclampsia [18, 21]. However, the predominance
of Th2 immunity was also reported in cases of recurrent
miscarriages [18, 22]; therefore, the Th1/Th2 paradigm is
also insuﬃcient to explain the mechanism that prevents the
rejection of the fetal allograft. Considering this scenario,
some authors have begun to expand this classic paradigm
by including responses that are characterized as Th17 and T-
regulating (Treg) [18, 23]. Cytokine IL-17 has proinﬂamma-
tory activity and characterizes the type-Th17 response [23,
24]; it has been described to induce inﬂammation in autoim-
mune diseases and acute graft rejection. In contrast, Treg
cells induce immunoregulation and tolerance by inhibiting
cytokine production and proliferation in T CD4+and CD8+
cells, immunoglobulin production by B cells, the cytotoxic
activity of natural-killer cells, and the maturation of den-
dritic cells, which results in tolerance induction [18, 25, 26].
Several paradigms have been proposed to explain the
modulation of the immunologic system in pregnancy [20].
More recently, Treg cells and type-3 T-helper response (Th3)
cells have been identiﬁed [27, 28] as a result of their
immunosuppressive action in pregnancy [29]. IL-10 appears
toplayafundamentalroleamongtheactivemechanismsthat
foster immunologic modulation in pregnancy [30, 31].
Thaxton and Sharma [32] proposed a contemporary
model that explains the modulatory balance of pro- and
anti-inﬂammatory cytokines in pregnancy development that
directly depends on the immunosuppressive action of IL-10.
Fromimplantationuntiltheendofatermpregnancy,the
interaction between pro- and anti-inﬂammatory cytokines,
of which IL-10 seems to be the key-cytokine, is fundamental
to promote normal pregnancy outcomes. Recent ﬁndings of
healthy pregnancy development show a global reduction of
proinﬂammatory cytokines, such as TNF-α,I L - 1 β,a n dI L -
6, and an increase of counterregulatory cytokines, such as
IL-10. According to these studies, these alterations reinforce
the role of immune modulation in the maintenance and
development of normal pregnancy [6].
We sought to clarify the true role of cytokines in human
pregnancy by conducting a review of the literature regarding
the action of the cytokines IL-10 and TNF-α in pregnancy;
we emphasized factors that are of interest to obstetrics.
2. Methods
The National Library of Medicine (Medline), Literatura Lat-
ino-Americana e do Caribe em Ciˆ encias da Sa´ ude (LILACS),
Scientiﬁc Electronic Library Online (Scielo), and PubMed
were consulted for this review. National and international
articles were located from the following key words: “cytoki-
nes,” “pregnancy,” “placenta,” “interleukin 10” and “tumor
necrosis factor-alpha.” In some searches, these words were
used in English. Initially, the articles were not limited to a
speciﬁc time period; however, those that were published in
the last 15 years were preferred. All authors evaluated the
studies that were included in the review.
3. Discussion
3.1. IL-10 and Pregnancy. IL-10 is a particularly intriguing
cytokine. In humans, it is characterized as pleiotropic and
has dual immunologic functions. This dual function means
that it is both stimulating and counterregulatory (immuno-
suppressive), which excludes it from the Th1/Th2 para-
digm; however, it was originally described as a cytokine that
displayed Th2 activity in rodents [6, 8, 9].
IL-10 is encoded on chromosome 1, and polymorphisms
inthegene’spromoterregioncaninterferewithitsregulation
[32, 33]. Its receptor is composed of two subunits, IL-
10R1 and IL-10R2, which are expressed in hematopoietic
and nonhematopoietic cells, including the cytotrophoblast.
The IL-10R1 receptor binds to the IL-10 protein; IL-10R2
is speciﬁc for initiating the signal transduction cascade that
is necessary for its function. These signals involve the so-
calledJanuskinases(Jak)andtranscriptionfactorscalledsig-
nal transducers and transcription activators (STATs). After
IL-10 binds to its receptor, the Jak enzymes phosphorylate
tyrosine residues on the receptor, and they subsequently
phosphorylate STAT in the cytoplasm. Sequentially, two
STAT proteins bind to each other and dissociate from the
receptor; the STAT dimers then migrate to the nucleus where
theybindtoDNAsequencesinthepromoterregionsofIL10-
responsive genes [32, 34].ISRN Obstetrics and Gynecology 3
IL-10 is the key cytokine at the beginning of pregnancy
because it is involved in various important events, which in-
clude placental formation. IL-10 has a protective eﬀect on
the fetal-placental unit because it inhibits the secretion of in-
ﬂammatory cytokines, such as IL-6, TNF-α,a n dI F N - γ [35];
jointly with IL-4 and IL-13, IL-10 seems to modulate tro-
phoblastic invasion [12]. According to Thaxton and Sharma
[32], IL-10 induces trophoblastic cells to produce vascular
endothelial growth factor C (VEGF C) and the aquaporin
(AQP1) system, which therefore stimulates placental angio-
genesis. At the end of pregnancy, IL-10 production pro-
gressively decreases, and the concentrations of inﬂammatory
cytokines predominate. According to Hanna et al. [36], this
change in the cytokine proﬁle is necessary to trigger sponta-
neous labor.
Other results have described decreased placental IL-10
production in the decidual region and the trophoblast in
pregnancies that are complicated by intrauterine growth
restriction [37],andthishasbeenconﬁrmedinexperimental
mice studies [38]. Conversely, higher IL-10 production was
observed in normal pregnancies when compared with high-
risk pregnancies; in the latter, the role of IL-10 in pregnancy
maintenance and development is noteworthy [39]. A recent
study on an experimental rat hypertension model revealed
the normalization of blood pressure levels and endothelial
functioninassociationwithIL-10administration.According
to those authors, the results reveal the importance of IL-10
action in conditions of exacerbated inﬂammatory response
[40].
In summary, IL-10 is an important cytokine for preg-
nancy maintenance and development. During this speciﬁc
period, its immunosuppressive action plays a key role in (i)
regulating the balance of pro- and anti-inﬂammatory signs
that orchestrate the adequate development of pregnancy and
(ii) in placental growth and remodeling, which are also
important for a favorable pregnancy outcome.
3.2. TNF-α and Pregnancy. TNF-α is an inﬂammatory cyto-
kine that belongs to the subpopulation of Th1 lymphocytes,
anditisencodedonchromosome6.Thiscytokineregulatesa
number of cell functions, including cell proliferation, diﬀer-
entiation, and apoptosis. Macrophages are the primary pro-
ducers of TNF-α and are also highly responsive to it [10].
TNF receptors are members of a large protein family, and
they exist in almost every type of cell that is involved in im-
munologic and inﬂammatory responses. These receptors ap-
pearastrimersinthecytoplasmicmembraneevenafterbind-
ing with TNF. When a cytokine binds to a type-I TNF recep-
tor (TNF-RI), either gene expression or apoptosis may oc-
cur. The binding of the TRAAD adaptor protein (a death
domain that is associated with the TNF receptor) occurs in
thereceptor’scytoplasmicdomain,andthisinteractionisfol-
lowed by the binding of two intermediate signaling fac-
tors, the TNF receptor-associated factor (TRAF) and the
receptor interaction protein; this process promotes the gene
expression of inﬂammatory mediators and antiapoptotic
proteins (survival). To promote caspase activation and ap-
optosis induction, the TRAAD adaptor protein binds to
the Fas-associated death domain (FAAD). Another action
mechanism of such cytokines includes the direct binding of
the cytoplasmic tails of other TNF receptor family members
to FAAD, which leads to apoptosis or to TRAF and thus
induces gene expression [34].
TNF-α increases with pregnancy development, and the
primary production source of this cytokine appears to be the
placenta [41]. Increased TNF-α can exacerbate insulin resis-
tance, which is normal in pregnancy; this favors the devel-
opment of GDM [14]. This characteristic is explained by
the inhibition of the tyrosine-kinase activity of the insulin
receptor in adipocytes and by the reduced phosphorylation
and activation of the insulin receptor-1 substrate (IRS-1),
which inhibits the insulin-signaling pathway [42]. Therefore,
TNF-α regulation during pregnancy can prevent the dele-
terious eﬀects of insulin resistance. According to some au-
thors, such veriﬁcation contradicts the classical concept that
insulin resistance in pregnancy is exclusively induced by pla-
cental hormones such as progesterone, human chorionic go-
nadotropin, prolactin, and estradiol [43].
Various studies have evaluated the concentrations of cir-
culating TNF-α in pregnant women with GDM; however,
the results remain controversial. Some studies observed in-
creased TNF-α in the blood of mothers who developed
GDM [44–49]. However, other studies did not conﬁrm such
ﬁndings [50].
Signiﬁcantly increased TNF-α production was observed
in the placenta and the subcutaneous adipose tissue in wo-
men with GDM and noncontrolled hyperglycemia when
compared with those with well-controlled GDM (i.e., nor-
moglycemic). According to the authors, these observations
suggest that the tissues of women with GDM increase the
release of TNF-α in response to hyperglycemia. Because
TNF-α is involved in the metabolic regulation of glucose,
lipids, and insulin resistance, these data are consistent with
the hypothesis that TNF-α is involved in GDM development
[14, 51].
Other eﬀects of TNF-α have been described in the new-
bornsofdiabeticandnondiabeticmothersandinotherhigh-
risk pregnancies. TNF-α decreases in the macrosomic oﬀ-
springofmotherswithGDM[45],andcontrarily,itincreases
in the placentas of pregnancies that are complicated by fetal
growth restriction [52]. Increased TNF-α concentrations
wereobservedinpregnantwomenwithpreeclampsia(hyper-
tension with proteinuria) when compared with those with
gestational hypertension (hypertension without protein-
uria).ThisresultsuggeststhatTNF-αcanbeusedasamark er
of severity in pregnancy hypertensive syndromes [13].
In summary, TNF-α is related to obesity, glucose intoler-
ance, type-2 diabetes mellitus, and GDM, and it is positive-
ly correlated with body mass index (BMI) [14, 44, 48,
53]. In pregnancy, TNF-α production in maternal adipose
tissue is enhanced by the placental production of TNF-α,
which makes it an important factor in the pathogenesis of
insulin resistance and GDM. This challenges the traditional
theory that reproductive hormones alone reduce insulin
sensitivity during pregnancy [14, 43, 49, 54]. Although this
has not been completely deﬁned, TNF-α seems to be the
marker of “demetabolism” and maternal glycemic control in4 ISRN Obstetrics and Gynecology
pregnancies that are complicated by type-2 diabetes mellitus
and GDM.
4. Conclusion andFutureProspects
The literature describes various functions of IL-10 and of
TNF-α in normal pregnancy. The actions of these cytokines
seem to be antagonistic and dependent on the balance
betweenthem,whichisorchestratedbythespeciﬁcimmuno-
suppressive action of IL-10. TNF-α has a characteristic
inﬂammatory action, and it is an additional diabetogenic
factor in pregnancy. The loss of the control of the production
of these cytokines, with increase of TNF-α, is related to
the risk for developing obstetric complications, particularly
recurrent fetal loss, GDM, hypertensive syndromes, and fetal
growth restriction. However, these results remain contro-
versial and are not completely reproducible. These issues
are attributed to the heterogeneity of the studies, which are
especially related to their source (in vivo compared with in
vitro), sample size (which is usually insuﬃcient), evalua-
tion methods (immunohistochemistry or molecular biology
tools), and the multiplicity of factors and conditions that
inﬂuence cytokine production. These issues are fundamental
a n dm u s tb ec o n s i d e r e di nf u t u r ei n v e s t i g a t i o n st op r o d u c e
moreconsistentresultsthatcanbeneﬁttheﬁeldofobstetrics.
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